Glucocorticoids and cyclic AMP selectively increase hepatic lipin-1 expression, and insulin acts antagonistically
Glucocorticoids and cyclic AMP selectively increase hepatic lipin-1 expression, and insulin acts antagonistically
复制标题
DOI:
10.1194/jlr.m800013-jlr200
复制
发表时间:
2008-05-01
影响因子:
6.5
通讯作者:
Brindley, David N.
中科院分区:
文献类型:
--
作者:
Manmontri, Boripant;Sariahmetoglu, Meltem;Brindley, David N.
Glucocorticoids (GCs) increase hepatic phosphatidate phosphatase (PAPI) activity. This is important in enhancing the liver's capacity for storing fatty acids as triacylglycerols (TAGs) that can be used subsequently for P-oxidation or VLDL secretion. PAN catalyzes the conversion of phosphatidate to diacylglycerol, a key substrate for TAG and phospholipid biosynthesis. PAPI enzymes in liver include lipin-1A and -1B (alternatively spliced isoforms) and two distinct gene products, lipin-2 and lipin-3. We determined the mechanisms by which the composite PAPI activity is regulated using rat and mouse hepatocytes. Levels of lipin-1A and -1B mRNA were increased by dexamethasone (dex; a synthetic GC), and this resulted in increased lipin-1 synthesis, protein levels, and PAPI activity. The stimulatory effect of dex on lipin-1 expression was enhanced by glucagon or cAMP and antagonized by insulin. Lipin-2 and lipin-3 mRNA were not increased by dex/cAMP, indicating that increased PAPI activity is attributable specifically to enhanced lipin-1 expression. This work provides the first evidence for the differential regulation of lipin activities. Selective lipin-1 expression explains the GC and cAMP effects on increased hepatic PAPI activity, which occurs in hepatic steatosis during starvation, diabetes, stress, and ethanol consumption.